Blue Jet Healthcare Limited — Investor Meet, 17-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Blue Jet Healthcare's Q3 FY26 saw revenue fall 40% YoY to Rs. 192.4 Cr, with EBITDA down 62% and PAT down 39%, impacted by product mix and inventory write-offs. Sequentially, revenue rose 16% driven by contrast media. Management is bullish on future growth, with groundbreaking for the Rs. 1,000 Cr Vizag plant planned for new APIs/intermediates. R&D is expanding in Hyderabad (Rs. 40 Cr investment), focusing on GLP-1s. The current PI/API de-stocking is expected to normalize in a quarter or two, with the end-molecule showing mid-double-digit growth. New product launches in contrast media and other APIs are expected to drive FY27.